

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)

2026 FIRST QUARTERLY REPORT

The Company and all the members of the board of directors confirm that all the information contained in this information disclosure is true, accurate and complete and that there is no false and misleading statement or material omission in this information disclosure.

This announcement is published in accordance with Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rules 13.09 and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The following is the 2026 first quarterly report of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**” or “**Hepalink**”, together with its subsidiaries referred to as the “**Group**”, “**we**” or “**our**”) for the three months ended March 31, 2026 (the “**Reporting Period**”). Its financial report was prepared in accordance with the PRC Accounting Standards and Accounting Regulations for Business Enterprises and was unaudited.

By order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, the PRC
April 29, 2026

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Ping; and the independent non-executive directors of the Company are Mr. Huang Peng, Mr. Yi Ming and Mr. Pu Hong.

IMPORTANT NOTICE:

1. The board of directors, directors and senior management of the Company undertake that the contents of the quarterly report are true, accurate and complete, without any false record, misrepresentation or material omission, and individually and jointly bear legal liabilities in this respect.
2. The person in charge of the Company, the person in charge of the accounting function and the person in charge of accounting firm, declare that they guarantee the financial information in the quarterly report is true, accurate and complete.
3. Whether the first quarterly financial accounting report has been audited
 Yes No

All directors attended the meeting of the board of directors held on April 29, 2026 at which the Company's first quarterly report for 2026 was considered and approved.

I. KEY FINANCIAL INFORMATION

(1) Major Accounting Information and Financial Indicators

Whether the Company is required to retroactively adjust or restate prior years' accounting information

Yes No

	The Reporting Period	Same period of last year	Increase/decrease for the Reporting Period over same period of last year (%)
Operating revenue (Yuan)	1,330,843,181.56	1,394,250,050.21	-4.55%
Net profit attributable to the shareholders of the listed company (Yuan)	187,571,621.23	156,590,188.54	19.79%
Net profit attributable to the shareholders of the listed company, net of extraordinary profits and losses (Yuan)	71,493,892.68	188,891,082.26	-62.15%
Net cash flows from operating activities (Yuan)	376,746,740.44	544,031,931.35	-30.75%
Basic earnings per share (Yuan/share)	0.1278	0.1067	19.78%
Diluted earnings per share (Yuan/share)	0.1278	0.1067	19.78%
Weighted average return on net assets	1.55%	1.28%	0.27%
	As at the end of the Reporting Period	As at the end of last year	Increase/decrease for the end of the Reporting Period over the end of last year (%)
Total assets (Yuan)	17,012,666,202.72	16,631,763,222.75	2.29%
Owners' equity attributable to the shareholders of the listed company (Yuan)	12,179,751,944.26	12,030,940,527.16	1.24%

(2) Items and Amounts of Extraordinary Profits and Losses

Applicable

Not Applicable

Unit: Yuan

Items	Amounts for the Reporting Period	Description
Gains or losses on disposal of non-current assets (including the write-off of the assets impairment provision)	-360,464.63	
Government grants included in the current profit and loss (other than those which are closely related to the normal operation of the Company, in line with national policies and regulations, granted in accordance with specified standards, and have a continuous impact on the profit or loss of the Company)	2,140,853.18	
Gain or loss on fair value changes arising from financial assets and financial liabilities held by non-financial entities, and gain or loss arising from the disposal of financial assets and financial liabilities, except for effective hedging transactions that are related to the normal operation of the Company	136,709,747.41	Including gain from changes in fair value of wealth management products, derivative financial assets, equity investments and fund investments totaling RMB114,194,111.44, and investment gains from the wealth management products, equity investments, fund investments etc. totalling RMB22,515,635.97 that were disposed of and acquired during the holding period
Other non-operating income and expenses apart from those stated above	349,016.45	
Less: Effect of income tax	22,746,332.81	
Effect of minority interest (after tax)	15,091.05	
Total	116,077,728.55	-

Details of other profit and loss items that meet the definition of extraordinary profit and losses.

Applicable Not Applicable

The Company has no other profit and loss items that meet the definition of extraordinary profit and losses.

Explanation given for defining an extraordinary profit and loss item as listed in the “Explanatory Announcement No. 1 on Information Disclosure by Companies Offering Their Securities to the Public — Extraordinary Profit and Loss” as a recurring profit and loss item

Applicable Not Applicable

The Company has not defined any extraordinary profit and loss item as listed in the “Explanatory Announcement No. 1 on Information Disclosure by Companies Offering Their Securities to the Public — Extraordinary Profit and Loss” as a recurring profit and loss item.

(3) Changes in Key Accounting Data and Financial Indicators and Reasons

Applicable Not Applicable

1. Balance sheet items

Unit: Yuan

Items	As at the end of the Reporting Period	As at the end of last year	Year-on-year increase/decrease	Reasons for changes
Cash and bank	1,786,653,446.39	1,346,117,834.28	32.73%	Mainly attributable to the net cash inflow from operating activities and the net cash inflow from financing activities during the Reporting Period
Other receivables	18,241,979.50	38,485,779.91	-52.60%	Mainly attributable to the increase in the recovery of other receivables during the Reporting Period
Non-current assets due within one year	58,794,151.36	90,976,370.44	-35.37%	Mainly attributable to the decrease in fixed deposits with terms of over one year due within one year during the Reporting Period

Items	As at the end of the Reporting Period	As at the end of last year	Year-on-year increase/decrease	Reasons for changes
Other non-current assets	313,954,400.11	195,324,208.81	60.74%	Mainly attributable to the increase in term deposits with a term of over one year during the Reporting Period
Short-term borrowings	2,723,562,460.67	1,770,460,098.85	53.83%	Mainly attributable to the increase in short-term borrowings during the Reporting Period
Employee remuneration payable	88,220,334.50	138,059,481.30	-36.10%	Mainly attributable to the payment of bonuses during the Reporting Period
Non-current liabilities due within one year	471,050,541.05	864,695,447.33	-45.52%	Mainly attributable to the repayment of a larger amount of long-term borrowings due within one year during the Reporting Period
Long-term borrowings	28,711,121.69	298,057,121.69	-90.37%	Mainly attributable to the repayment of a larger amount of long-term borrowings during the Reporting Period

2. Income statement items

Unit: Yuan

Items	The Reporting Period	Same period of last year	Year-on-year increase/decrease	Reasons for changes
Finance costs	127,866,116.96	-56,508,230.69	326.28%	Mainly attributable to exchange losses resulting from exchange rate fluctuations during the Reporting Period, as compared to exchange gains for the corresponding period of last year
Investment income (losses are represented by “-”)	30,331,399.46	20,292,064.76	49.47%	Mainly attributable to the recognition of investment income from project dividends received during the Reporting Period
Gain on fair value changes (losses are represented by “-”)	114,194,111.44	-45,301,562.05	352.08%	Mainly attributable to the gains on fair value changes of financial assets during the Reporting Period
Credit impairment losses (losses are represented by “-”)	-9,759,792.81	476,178.44	2,149.61%	Mainly attributable to the increase in credit impairment losses recognised for receivables during the Reporting Period
Assets impairment losses (losses are represented by “-”)	-2,027,283.52	44,094.91	4,697.55%	Mainly attributable to the increase in asset impairment losses recognised for inventories during the Reporting Period
Gain on disposal of assets (losses are represented by “-”)	-330,951.09	1,288,820.50	125.68%	Mainly attributable to the increase in loss on disposal of assets during the Reporting Period
Less: Non-operating expenses	136,513.26	1,330,835.62	-89.74%	Mainly attributable to the decrease in non-operating expenses during the Reporting Period

3. Cash flow items

Unit: Yuan

Items	The Reporting Period	Same period of last year	Year-on-year increase/decrease	Reasons for changes
Net cash flows from operating activities	376,746,740.44	544,031,931.35	-30.75%	Mainly attributable to the year-on-year decrease in tax refunds received during the Reporting Period
Net cash flows from financing activities	269,696,882.57	22,602,544.83	1,093.21%	Mainly attributable to the year-on-year increase in cash received from the Company's new borrowings during the Reporting Period
Net increase in cash and cash equivalents	422,488,827.11	318,638,044.68	32.59%	Mainly attributable to the combined effect of the decrease in net cash flows from operating activities and the increase in net cash flows from financing and investing activities during the Reporting Period

II. INFORMATION OF THE SHAREHOLDERS

(1) Table of total number of ordinary shareholders, the number of preferred shareholders whose voting rights have been restored and shareholdings of the top 10 shareholders

Unit: Share(s)

Total number of ordinary shareholders as at the end of the Reporting Period		Total number of preferred shareholders (if any) whose voting rights have been restored as at the end of the Reporting Period				
24,951		0				
Shareholding of the top 10 shareholders (excluding shares lent through securities lending and refinancing)						
Name of shareholder	Nature of shareholder	Shareholding percentage (%)	Number of shares held	Number of shares held subject to selling restrictions	Status of shares pledged, marked or frozen	
					Status of shares	Number
Shenzhen Leren Technology Co., Ltd.	Domestic non-state-owned legal person	32.31%	474,029,899	0	N/A	0
Gongqingcheng Jintiantu Investment Partnership (Limited Partnership)	Domestic non-state-owned legal person	27.81%	408,041,280	0	N/A	0
HKSCC NOMINEES LIMITED	Foreign legal person	15.00%	220,037,480	0	N/A	0
Gongqingcheng Shuidi Shichuan Investment Partnership (Limited Partnership)	Domestic non-state-owned legal person	3.16%	46,425,600	0	N/A	0
Hong Zejun	Domestic natural person	2.80%	41,080,000	0	N/A	0
Gongqingcheng Feilaishi Investment Co., Ltd.	Domestic non-state-owned legal person	2.75%	40,320,000	0	N/A	0
Shenzhen Hepalink Pharmaceutical Co., Ltd. – Employee Share Scheme II	Others	1.03%	15,118,035	0	N/A	0
Hong Kong Securities Clearing Company Limited	Foreign legal person	0.73%	10,690,437	0	N/A	0
Lu Yang	Domestic natural person	0.54%	7,980,000	0	N/A	0
Shenzhen Hepalink Pharmaceutical Co., Ltd. – Employee Share Scheme III	Others	0.26%	3,886,264	0	N/A	0

Shareholding of the top 10 shareholders who are not subject to selling restrictions (excluding shares lent through refinancing, locked-up shares of senior management)			
Name of shareholder	Number of shares held not subject to selling restrictions	Type of shares	
		Type of shares	Number
Shenzhen Leren Technology Co., Ltd.	474,029,899	RMB ordinary shares	474,029,899
Gongqingcheng Jintiantu Investment Partnership (Limited Partnership)	408,041,280	RMB ordinary shares	408,041,280
HKSCC NOMINEES LIMITED	220,037,480	Overseas listed foreign shares	220,037,480
Gongqingcheng Shuidi Shichuan Investment Partnership (Limited Partnership)	46,425,600	RMB ordinary shares	46,425,600
Hong Zejun	41,080,000	RMB ordinary shares	41,080,000
Gongqingcheng Feilaishi Investment Co., Ltd.	40,320,000	RMB ordinary shares	40,320,000
Shenzhen Hepalink Pharmaceutical Co., Ltd. – Employee Share Scheme II	15,118,035	RMB ordinary shares	15,118,035
Hong Kong Securities Clearing Company Limited	10,690,437	RMB ordinary shares	10,690,437
Lu Yang	7,980,000	RMB ordinary shares	7,980,000
Shenzhen Hepalink Pharmaceutical Co., Ltd. – Employee Share Scheme III	3,886,264	RMB ordinary shares	3,886,264
Explanations on the connected relationship or acting in concert relationship among above shareholders	The shareholders (partners) of Shenzhen Leren Technology Co., Ltd. and Gongqingcheng Jintiantu Investment Partnership (Limited Partnership) are Li Li and Li Tan, the shareholder of Gongqingcheng Feilaishi Investment Co., Ltd. is Li Li, and the partners of Gongqingcheng Shuidi Shichuan Investment Partnership (Limited Partnership) are Shan Yu and Li Tan. Li Li and Li Tan are the spouse of each other. Shan Yu is the elder brother of Li Tan. Shan Yu has participated in Employee Share Scheme II of the Company with a participation share of 38.88% of that Employee Share Scheme. Save for the aforesaid information, the Company is not aware of any related relationship among the other top 10 shareholders or parties acting in concert.		
Explanation on the top 10 shareholders' participation in financing and securities lending business (if any)	HKSCC NOMINEES LIMITED held shares on behalf of multiple clients, and its participation in margin financing and securities lending is unknown; Hong Zejun held 41,080,000 company shares through the customer credit transaction guarantee securities account of China Galaxy Securities Co., Ltd.; Lu Yang held 6,480,000 company shares through ordinary securities accounts, held 1,500,000 company shares through client account of collateral securities for margin trading at China CICC Wealth Management Securities Company Limited, with an actual total shareholding of 7,980,000 company shares.		

Lending of shares by shareholders holding more than 5% of the shares, top 10 shareholders and top 10 shareholders with unrestricted tradable shares in refinancing business

Applicable Not Applicable

The top 10 shareholders and the top 10 shareholders with unrestricted tradable shares changed from the previous period due to the lending/repayment of refinancing

Applicable Not Applicable

(2) Statement of the total number of preferred shareholders of the Company and shareholdings of the top 10 preferred shareholders

Applicable Not Applicable

III. OTHER IMPORTANT EVENTS

Applicable Not Applicable

IV. QUARTERLY FINANCIAL STATEMENTS

(1) Financial Statements

1. Consolidated Balance Sheet

Prepared by Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

March 31, 2026

Unit: Yuan

Items	Balance at the end of the period	Balance at the beginning of the year
Current assets:		
Cash and bank	1,786,653,446.39	1,346,117,834.28
Provision of settlement fund		
Placements with banks and other financial institutions		
Financial assets held for trading	1,718,057,779.57	1,483,998,368.22
Derivative financial assets		
Bills receivable	680,000.00	91,200.52
Accounts receivable	1,364,886,411.87	1,367,427,787.22
Receivables financing		
Prepayments	75,973,790.01	74,243,331.30
Premiums receivable		
Reinsurance accounts receivable		
Reinsurance contract reserves receivable		
Other receivables	18,241,979.50	38,485,779.91
Including: Interests receivable		
Dividends receivable		
Financial assets held under resale agreements		
Inventories	4,182,801,863.46	4,446,648,184.55
Including: data resources		
Contract assets		
Assets held for sale		
Non-current assets due within one year	58,794,151.36	90,976,370.44
Other current assets	373,901,724.80	302,931,911.71
Total current assets	9,579,991,146.96	9,150,920,768.15

Items	Balance at the end of the period	Balance at the beginning of the year
Non-current assets:		
Loans and advances to customers		
Debt investments		
Other debt investments		
Long-term receivables		
Investment in associates	194,013,176.42	223,668,936.91
Investments in other equity instruments	608,986,958.60	622,509,453.67
Other non-current financial assets	935,760,879.48	920,164,861.75
Investment properties		
Fixed assets	2,194,186,885.07	2,261,499,887.02
Construction in progress	62,728,448.23	60,698,969.85
Biological assets for production		
Oil and gas assets		
Right-of-use assets	56,499,848.73	66,300,875.31
Intangible assets	308,994,070.01	326,572,806.47
Including: data resources		
Development costs	542,476.01	542,476.01
Including: data resources		
Goodwill	2,268,830,049.37	2,304,701,657.80
Long-term prepaid expenses	172,382,256.71	178,417,537.99
Deferred income tax assets	315,795,607.02	320,440,783.01
Other non-current assets	313,954,400.11	195,324,208.81
Total non-current assets	7,432,675,055.76	7,480,842,454.60
Total assets	17,012,666,202.72	16,631,763,222.75

Items	Balance at the end of the period	Balance at the beginning of the year
Current liabilities:		
Short-term borrowings	2,723,562,460.67	1,770,460,098.85
Borrowing from the central bank		
Placements from banks and other financial institutions		
Financial liabilities held for trading		
Derivative financial liabilities		
Bills payable	4,040,988.90	
Accounts payable	284,714,791.47	257,067,222.23
Receipts in advance	23,191,585.08	23,191,585.08
Contract liabilities	230,144,109.69	227,596,122.80
Financial assets sold under repurchase agreements		
Receipt of deposits and deposits from other banks		
Customer deposits for trading in securities		
Customer deposits for undertaking securities		
Employee remuneration payable	88,220,334.50	138,059,481.30
Taxes payable	139,663,965.42	149,063,424.13
Other payables	490,089,032.98	516,998,422.04
Including: Interests payable		
Dividends payable		
Fees and commissions payable		
Reinsurance accounts payable		
Liabilities held for sale		
Non-current liabilities due within one year	471,050,541.05	864,695,447.33
Other current liabilities		6,243,783.54
Total current liabilities	4,454,677,809.76	3,953,375,587.30

Items	Balance at the end of the period	Balance at the beginning of the year
Non-current liabilities:		
Provision for insurance contracts		
Long-term borrowings	28,711,121.69	298,057,121.69
Bonds payable		
Including: Preferred shares		
Perpetual bonds		
Lease liabilities	35,435,551.81	40,318,016.84
Long-term payables	535,524.04	521,544.16
Long-term employee remuneration payable		
Contingent liabilities	9,518,600.79	9,669,095.76
Deferred income	40,886,014.51	42,583,734.76
Deferred income tax liabilities	214,171,702.71	207,071,468.93
Other non-current liabilities		
Total non-current liabilities	329,258,515.55	598,220,982.14
Total liabilities	4,783,936,325.31	4,551,596,569.44
Owners' equity:		
Share capital	1,467,296,204.00	1,467,296,204.00
Other equity instruments		
Including: Preferred shares		
Perpetual bonds		
Capital reserves	5,863,855,014.44	5,863,855,014.44
Less: Treasury stock		
Other comprehensive income	95,202,457.18	133,962,661.31
Special reserves		
Surplus reserves	545,376,458.31	545,376,458.31
Provision for general risks		
Retained earning	4,208,021,810.33	4,020,450,189.10
Total equity attributable to owners of the parent company	12,179,751,944.26	12,030,940,527.16
Non-controlling interest	48,977,933.15	49,226,126.15
Total owners' equity	12,228,729,877.41	12,080,166,653.31
Total liabilities and owners' equity	17,012,666,202.72	16,631,763,222.75

Legal representative:
Li Li

Person in charge of
accounting function:
Chen Juan

Person in charge of
accounting firm:
Chen Juan

2. Consolidated Income Statement

Unit: Yuan

Items	Amount for current period	Amount for previous period
I. Total operating revenue	1,330,843,181.56	1,394,250,050.21
Including: Operating revenue	1,330,843,181.56	1,394,250,050.21
Interest income		
Insurance premiums earned		
Fee and commission income		
II. Total operating costs	1,258,030,677.80	1,194,258,578.20
Including: Operating costs	876,307,888.05	1,013,068,235.61
Interest expenses		
Fee and commission expenses		
Insurance withdrawal payment		
Net claims expenses		
Net provisions withdrew for insurance liability contract		
Insurance policy dividend paid		
Reinsurance costs		
Taxes and surcharges	8,108,184.65	6,501,910.21
Selling expenses	116,704,178.91	93,470,283.27
Administration expenses	92,605,195.61	97,732,580.23
Research and development expenses	36,439,113.62	39,993,799.57
Finance costs	127,866,116.96	-56,508,230.69
Including: Interest expenses	13,050,969.16	22,447,163.34
Interest income	8,172,607.15	9,254,210.88
Add: Other gains	2,140,853.18	2,189,273.64
Investment income (losses are represented by “-”)	30,331,399.46	20,292,064.76
Including: Investment income from associates and joint ventures	7,815,763.49	16,447,715.69
Revenue from derecognition of financial assets measured at amortized cost		
Exchange gain (losses are represented by “-”)		
Gains on net exposure hedges (losses are represented by “-”)		

Items	Amount for current period	Amount for previous period
Gains on fair value changes (losses are represented by “-”)	114,194,111.44	-45,301,562.05
Credit impairment losses (losses are represented by “-”)	-9,759,792.81	476,178.44
Asset impairment losses (losses are represented by “-”)	-2,027,283.52	44,094.91
Gains from disposal of assets (losses are represented by “-”)	-330,951.09	1,288,820.50
III. Operating profit (losses are represented by “-”)	207,360,840.42	178,980,342.21
Add: Non-operating income	456,016.17	589,786.50
Less: Non-operating expenses	136,513.26	1,330,835.62
IV. Total profit (total losses are represented by “-”)	207,680,343.33	178,239,293.09
Less: Income tax expense	20,308,221.79	22,070,103.64
V. Net profit (net losses are represented by “-”)	187,372,121.54	156,169,189.45
(I) Classification by going concern basis		
1. Net profit from continuing operations (net losses are represented by “-”)	187,372,121.54	156,169,189.45
2. Net profit from discontinued operations (net losses are represented by “-”)		
(II) Classification by ownership of the equity		
1. Net profit attributable to owners of the parent company	187,571,621.23	156,590,188.54
2. Profit or loss attributable to minority shareholders	-199,499.69	-420,999.09
VI. Other comprehensive income, net of tax	-38,808,897.44	-18,254,137.11
Other comprehensive income attributable to owners of the parent company, net of tax	-38,760,204.13	-18,249,964.04
(I) Other comprehensive income that cannot be reclassified into the profit or loss	-7,291,973.92	29,149,201.63
1. Changes arising from re-measurement of defined benefit plans		3,342,829.03
2. Other comprehensive income that cannot be transferred into profit or loss under equity method		
3. Changes in fair value of investments in other equity instruments	-7,291,973.92	25,806,372.60
4. Changes in fair value of credit risks of the enterprise		
5. Others		

Items	Amount for current period	Amount for previous period
(II) Other comprehensive income to be reclassified into the profit or loss	-31,468,230.21	-47,399,165.67
1. Other comprehensive income that can be transferred into profit or loss under equity method		
2. Changes in fair value of other debt investments		
3. Financial assets reclassified into other comprehensive income		
4. Credit impairment provision for other debt investments		
5. Cash flow hedging reserve		
6. Exchange differences on translation of financial statements denominated in foreign currencies	-31,468,230.21	-47,399,165.67
7. Others		
Other comprehensive income attributable to minority shareholders, net of tax	-48,693.31	-4,173.07
VII. Total comprehensive income	148,563,224.10	137,915,052.34
Total comprehensive income attributable to owners of the parent company	148,811,417.10	138,340,224.50
Total comprehensive income attributable to minority shareholders	-248,193.00	-425,172.16
VIII. Earnings per share:		
(I) Basic earnings per share	0.1278	0.1067
(II) Diluted earnings per share	0.1278	0.1067

Net profit realised by the combined party before the combination in respect of business combination under common control during current period: RMB0, net profit realised by the combined party during previous period: RMB0.

Legal representative:
Li Li

Person in charge of
accounting function:
Chen Juan

Person in charge of
accounting firm:
Chen Juan

3. Consolidated Cash Flow Statement

Unit: Yuan

Items	Amount for current period	Amount for previous period
I. Cash flows from operating activities:		
Cash received from the sale of goods and rendering of services	1,377,718,329.34	1,327,258,705.88
Net increase in customers and interbank deposits		
Net increase in borrowing from the central bank		
Net increase in placement from other financial institutes		
Cash received from premiums under original insurance contract		
Net cash received from reinsurance business		
Net increase in deposits of policy holders and investment		
Cash received from interest, fee and commissions		
Net increase in placements from banks and other financial institutions		
Net increase in cash received from repurchase operation		
Net cash received from securities trading agency services		
Refunds of taxes received	373,750.29	127,196,056.72
Cash received from other related operating activities	6,825,723.12	47,510,298.94
Sub-total of cash inflows from operating activities	1,384,917,802.75	1,501,965,061.54
Cash paid for purchasing goods and receiving services	502,496,351.38	504,603,143.23
Net increase in loans and advances to customers		
Net increase in deposits with central bank and interbank		
Cash paid for compensation payments under original insurance contract		
Net increase in placements with banks and other financial institutions		
Cash paid for interest, fees and commissions		
Cash paid for insurance policy dividend		
Cash paid to and on behalf of employees	249,435,839.51	225,883,127.82
Cash paid for all types of taxes	104,954,242.53	71,329,471.04
Cash paid to other related operating activities	151,284,628.89	156,117,388.10
Sub-total of cash outflows from operating activities	1,008,171,062.31	957,933,130.19
Net cash flows from operating activities	376,746,740.44	544,031,931.35

Items	Amount for current period	Amount for previous period
II. Cash flows from investment activities:		
Cash received from realisation of investments	670,372,008.64	464,000,000.00
Cash received from investment income	121,100,365.99	8,008,952.23
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	39,370.00	1,310,185.20
Net cash received from disposal of subsidiaries and other operating entities	20,700,000.00	
Cash received from other investment related activities	55,371,205.75	132,056,984.81
Sub-total of cash inflows from investing activities	867,582,950.38	605,376,122.24
Cash paid on purchase of fixed assets, intangible assets and other long-term assets	21,143,817.29	41,013,022.80
Cash paid for investments	837,830,060.40	664,015,099.31
Net increase in secured loans		
Net cash paid for the acquisition of subsidiaries and other operating entities		
Cash paid for other investment related activities	214,008,050.00	157,900,000.00
Sub-total of cash outflows from investing activities	1,072,981,927.69	862,928,122.11
Net cash flows from investing activities	-205,398,977.31	-257,551,999.87
III. Cash flows from financing activities:		
Cash received from capital contributions		
Including: Cash received by subsidiaries from capital contributions by minority shareholders		
Cash received from borrowings	1,830,600,000.00	750,396,287.53
Cash received from other related financing activities		
Sub-total of cash inflows from financing activities	1,830,600,000.00	750,396,287.53
Cash paid on repayment of debts	1,534,844,370.41	694,559,937.21
Cash paid on distribution of dividends, profits or settlement of interest	15,109,505.06	24,391,010.01
Including: Dividend and profit paid to minority shareholders by subsidiaries		
Cash paid for other related financing activities	10,949,241.96	8,842,795.48
Sub-total of cash outflows from financing activities	1,560,903,117.43	727,793,742.70
Net cash flows from financing activities	269,696,882.57	22,602,544.83

Items	Amount for current period	Amount for previous period
IV. Effect of fluctuations in exchange rates on cash and cash equivalents	-18,555,818.59	9,555,568.37
V. Net increase in cash and cash equivalents	422,488,827.11	318,638,044.68
Add: Balance of cash and cash equivalents at the beginning of the period	1,191,393,759.75	1,421,826,833.85
VI. Balance of cash and cash equivalents at the end of the period	1,613,882,586.86	1,740,464,878.53

(2) Adjustments to the financial statements as at the beginning of the year due to the application of new accounting standards for the first time since 2026

Applicable Not Applicable

(3) Audit Report

Whether the first quarterly financial accounting report has been audited

Yes No

The first quarterly financial accounting report of the Company has not been audited.

Board of Directors of Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
April 29, 2026